5 news items
Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews
KYMR
24 May 24
conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
KYMR
23 May 24
highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024
Kymera Therapeutics Present's Clinical Data From The Ongoing Phase 1 Trial Of STAT3 Degrader KT-333 At EHA Annual Meeting June 13-16, 2024, In Madrid, Spain
KYMR
14 May 24
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
KYMR
14 May 24
highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
KYMR
22 Apr 24
market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments
- Prev
- 1
- Next